Blocking tau, a hallmark of Alzheimer’s disease, may benefit ALS patients.
- Previous research has suggested that an inhaled anesthetic called sevoflurane may promote the brain changes of Alzheimer’s disease. A new study in cells and mice reveals that sevoflurane causes the Alzheimer’s-related protein tau to leave neurons and enter immune cells (microglia) in the brain, ulti
- The findings provide new insights on tau spreading and how it contributes to the brain changes of Alzheimer’s disease.
Zhongcong Xie, MD, PhD
These data demonstrate anesthesia-associated tau spreading and its consequences.This tau spreading could be prevented by inhibitors of tau phosphorylation or extracellular vesicle generation.
Director, Geriatric Anesthesia Research Unit, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital
BOSTON – During the development and progression of Alzheimer’s disease, a protein called tau accumulates and spreads in the brain. Understanding the mechanisms behind tau spread—and its consequences—may point to new prevention and treatment strategies for Alzheimer’s disease and other forms of dementia. New insights now come from research that was led by investigators at Massachusetts General Hospital (MGH) and involves an anesthetic known to affect cognitive function. The findings are published in Communications Biology.
The scientists note that inflammation plays an important role in Alzheimer’s disease, and microglia—immune cells that reside in the brain—are thought to be involved in this process by producing an inflammatory molecule called interleukin-6. To see if tau stimulates microglia to drive the development of Alzheimer’s disease pathology, the MGH investigators and their colleagues conducted experiments with an inhaled anesthetic called sevoflurane. Their previous work showed that sevoflurane can cause a change (specifically, phosphorylation, or the addition of phosphate) to tau that leads to cognitive impairment in mice. Other researchers have also found that sevoflurane and certain other anesthetics may affect cognitive function.
In this current study, the team developed a novel method to measure tau levels, called nanobeam-sensor technology. “The nanobeam sensor is ultrasensitive, requires a small volume, and can measure low concentrations of molecules, including tau and phosphorylated tau,” says co–lead author Feng Liang, MD, PhD, an instructor in the Department of Anesthesia, Critical Care and Pain Medicine (DACCPM) at MGH.
The group conducted experiments in mice and cells and discovered that sevoflurane causes tau to leave neurons and enter microglia, where it stimulates the cells’ production of interleukin-6, which in turn leads to inflammation and cognitive impairment. The trafficking of tau from neurons to microglia involves tau phosphorylation and membrane-bound carriers called extracellular vesicles that are released from cells.
“These data demonstrate anesthesia-associated tau spreading and its consequences,” says senior author Zhongcong Xie, MD, PhD, director of the Geriatric Anesthesia Research Unit in the DACCPM. “This tau spreading could be prevented by inhibitors of tau phosphorylation or extracellular vesicle generation.”
Sevoflurane did not increase the release of lactate dehydrogenase, a molecule with a similar size and weight as tau, from neurons. “This finding indicates that neuronal cell membranes and cell viability were not compromised by sevoflurane treatment and that the sevoflurane-induced leaking of tau was not a passive process,” says co–lead author Yuanlin Dong, MD, a research fellow in the department.
Another inhaled anesthetic called desflurane did not have the same effects as sevoflurane. “Our results suggest that the anesthetics sevoflurane and desflurane may have different impacts on tau phosphorylation and tau spreading. More important, sevoflurane may be used as a clinically relevant tool to study tau spreading and its underlying mechanisms,” says Xie. “We hope this work will lead to more research on anesthesia, tau proteins, and Alzheimer’s disease pathology that will ultimately improve care for patients.”
Additional co-authors are Lining Huang, MD, PhD, MGH DACCPM and Hebei Medical University, China; Fang Fang, MD, PhD, MGH DACCPM and Fudan University, China; Guang Yang, PhD, Columbia University Medical Center; Rudolph E. Tanzi, PhD, MassGeneral Institute for Neurodegenerative Disease; Yiying Zhang, MD, PhD, MGH DACCPM; and Qimin Quan, PhD, Rowland Institute of Harvard University and NanoMosaic.
The study was supported by the National Institutes of Health, including both the National Institutes of Aging and the Eunice Kennedy Shriver National Institute of Child Health & Human Development.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
- Press Release
- Aug | 20 | 2021
Irisin is an important mediator of the neuroprotective benefits of exercise in the brain, holding potential for treating Alzheimer’s disease and other neurodegenerative diseases.
- Press Release
- Jul | 14 | 2021
Interleukin-3 may reprogram immune responses in the brain that cause cell death and lead to dementia.
- Press Release
- Jul | 8 | 2021
La terapia génica con "dedos de cinc" puede ayudar a tratar la enfermedad de Alzheimer, según un estudio en animales
Los investigadores han utilizado una estrategia de ingeniería genética para reducir drásticamente los niveles de tau—una proteína clave que se acumula y se enreda en el cerebro durante el desarrollo de la enfermedad de Alzheimer—en un modelo animal de la enfermedad.
- Press Release
- Jul | 6 | 2021
There is no clinical evidence that the monoclonal antibody aducanumab is beneficial to patients with cerebral amyloid angiopathy, according to officers with the International Cerebral Amyloid Angiopathy Association.
- Press Release
- May | 19 | 2021
A key protein must be cut to create amyloid beta. Groundbreaking work identifies the “lipid raft” in nerve cells where this process occurs, which could offer new targets for drug therapy.